ArticleProceedings of the National Academy of Sciences of the United States of America2011
Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 3 syntheses or guidelines pooled it, 139 citations in OpenAlex.
- Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.Clinical pharmacology and therapeutics · 2021Guideline
- Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts.Behavior genetics · 2016Pooled it
- Systematic Review and Meta-Analysis of Genetic Risk of Developing Chronic Postsurgical Pain.The journal of painPooled it
- Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype-genotype assessment.Addiction biology · 2024Trial
- Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.Alcoholism, clinical and experimental research · 2020Trial
- Independent association of tobacco use with opioid use disorder in patients of European ancestry with chronic non-cancer pain.Drug and alcohol dependence · 2020Trial
- Impact of chronic migraine attacks and their severity on the endogenous μ-opioid neurotransmission in the limbic system.NeuroImage. Clinical · 2019Trial
- The concept of exposure when selecting comparison groups for determining individual susceptibility to addiction to cigarette smoking.PloS one · 2019Trial
- Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteers.Psychopharmacology · 2015Trial
- Multi-Locus Pro-Dopaminergic Restoration of Reward Brain Circuitry in Reward Deficiency Rescinds Mono-Pharmaceutical Targeting.Neurology (E-Cronicon) · 2025Article
- Genomic factors associated with substance use disorder relapse: A critical review.Addictive behaviors reports · 2024Review
- Understanding individual variability in opioid responses: A call to arms.Addiction biology · 2024Article
- Genetic polymorphisms in the serotonin, dopamine and opioid pathways influence social attention in rhesus macaques (Macaca mulatta).PloS one · 2023Article
- Unique and joint associations of polygenic risk for major depression and opioid use disorder with endogenous opioid system function.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Article
- Nicotine and opioid co-dependence: Findings from bench research to clinical trials.Neuroscience and biobehavioral reviews · 2022Review
- Translational Research in Nicotine Addiction.Cold Spring Harbor perspectives in medicine · 2021Review
- Association Study of Opioid Receptor Delta-Type 1 (OPRD1) Gene Variants with Nicotine Dependence in an Iranian Population.Journal of molecular neuroscience : MN · 2021Article
- Can Implementation of Genetics and Pharmacogenomics Improve Treatment of Chronic Low Back Pain?Pharmaceutics · 2020Review
- Differential sensitivity of human neurons carrying μ opioid receptor (MOR) N40D variants in response to ethanol.Alcohol (Fayetteville, N.Y.) · 2020Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
Evidence points to the endogenous opioid system, and the mu-opioid receptor (MOR) in particular, in mediating the rewarding effects of drugs of abuse, including nicotine. A single nucleotide polymorphism (SNP) in the human MOR gene (OPRM1 A118G) has been shown to alter receptor protein level in preclinical models and smoking behavior in humans. To clarify the underlying mechanisms for these associations, we conducted an in vivo investigation of the effects of OPRM1 A118G genotype on MOR binding potential (BP(ND) or receptor availability). Twenty-two smokers prescreened for genotype (12 A/A, 10 */G) completed two [(11)C]carfentanil positron emission tomography (PET) imaging sessions following overnight abstinence and exposure to a nicotine-containing cigarette and a denicotinized cigarette. Independent of session, smokers homozygous for the wild-type OPRM1 A allele exhibited significantly higher levels of MOR BP(ND) than smokers carrying the G allele in bilateral amygdala, left thalamus, and left anterior cingulate cortex. Among G allele carriers, the extent of subjective reward difference (denicotinized versus nicotine cigarette) was associated significantly with MOR BP(ND) difference in right amygdala, caudate, anterior cingulate cortex, and thalamus. Future translational investigations can elucidate the role of MORs in nicotine addiction, which may lead to development of novel therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.